Publicacions en què col·labora amb Estanislao Nistal Villán (11)

2023

  1. Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution

    Frontiers in Immunology, Vol. 14

2022

  1. Broad virus inactivation using inorganic micro/nano-particulate materials

    Materials Today Bio, Vol. 13

  2. Targeting Signaling Pathway Downstream of RIG-I/MAVS in the CNS Stimulates Production of Endogenous Type I IFN and Suppresses EAE

    International Journal of Molecular Sciences, Vol. 23, Núm. 19

2021

  1. Linking the Expression of Therapeutic Genes to Unfolded Protein Response: A New Option for Anti-Hepatitis B Virus Gene Therapy

    Human Gene Therapy, Vol. 32, Núm. 7-8, pp. 341-348

2018

  1. TMEM173 Alternative Spliced Isoforms Modulate Viral Replication through the STING Pathway

    ImmunoHorizons, Vol. 2, Núm. 11, pp. 363-376

2016

  1. A versatile vector for in vivo monitoring of type I interferon induction and signaling

    PLoS ONE, Vol. 11, Núm. 3

  2. Interferon alpha bioactivity critically depends on Scavenger receptor class B type I function

    OncoImmunology, Vol. 5, Núm. 8

  3. Mitochondrial respiratory-chain adaptations in macrophages contribute to antibacterial host defense

    Nature Immunology, Vol. 17, Núm. 9, pp. 1037-1045

2015

  1. A RIG-I 2CARD-MAVS200 Chimeric Protein Reconstitutes IFN-β Induction and Antiviral Response in Models Deficient in Type i IFN Response

    Journal of Innate Immunity, Vol. 7, pp. 466-481

  2. Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model

    Molecular Cancer, Vol. 14, Núm. 1

2012

  1. Structure and dynamics of the second CARD of human RIG-I provide mechanistic insights into regulation of RIG-I activation

    Structure, Vol. 20, Núm. 12, pp. 2048-2061